(Q33870255)

29 July 2017

1 reference

title

Chronic cholestatic diseases (English)

1 reference

29 July 2017

Poupon R

1

1 reference

29 July 2017

Chazouillères O

series ordinal

2

1 reference

29 July 2017

Poupon RE

series ordinal

3

1 reference

29 July 2017

publication date

1 January 2000

1 reference

29 July 2017

published in

Journal of Hepatology

1 reference

29 July 2017

volume

32

1 reference

29 July 2017

issue

1 Suppl

1 reference

29 July 2017

page(s)

129-140

1 reference

Congenital diseases of intrahepatic bile ducts: variations on the theme "ductal plate malformation"

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Biliary atresia: current concepts and research directions. Summary of a symposium

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Features of Alagille syndrome in 92 patients: frequency and relation to prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Mutations in the human Jagged1 gene are responsible for Alagille syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Spectrum and frequency of jagged1 (JAG1) mutations in Alagille syndrome patients and their families

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Mutations in JAGGED1 gene are predominantly sporadic in Alagille syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Genetic basis of progressive familial intrahepatic cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Phosphatidylcholine translocase: a physiological role for the mdr2 gene

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Familial giant cell hepatitis associated with synthesis of 3 beta, 7 alpha-dihydroxy-and 3 beta,7 alpha, 12 alpha-trihydroxy-5-cholenoic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Delta 4-3-oxosteroid 5 beta-reductase deficiency described in identical twins with neonatal hepatitis. A new inborn error in bile acid synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Familial Giant Cell Hepatitis with Low Bile Acid Concentrations and Increased Urinary Excretion of Specific Bile Alcohols: A New Inborn Error of Bile Acid Synthesis?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinicopathologic and serologic correlations in 200 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Antibodies to carbonic anhydrase in patients with immune cholangiopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Frequency and nature of the variant syndromes of autoimmune liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

The human biliary epithelial cell plasma membrane antigen in primary biliary cirrhosis: pyruvate dehydrogenase X?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Expression of pyruvate-dehydrogenase complex PDC-E2 on biliary epithelial cells induced by lymph nodes from primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

In situ nucleic acid hybridization of pyruvate dehydrogenase complex-E2 in primary biliary cirrhosis: pyruvate dehydrogenase complex-E2 messenger RNA is expressed in hepatocytes but not in biliary epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

In situ nucleic acid detection of PDC-E2, BCOADC-E2, OGDC-E2, PDC-E1alpha, BCOADC-E1alpha, OGDC-E1, and the E3 binding protein (protein X) in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

T lymphocytes from patients with primary biliary cirrhosis produce reduced amounts of lymphotoxin, tumor necrosis factor and interferon-gamma upon mitogen stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Enhanced expression of TNFα in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Analysis of serum cytokine levels in primary biliary cirrhosis patients and healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Genetic abnormalities of immunoregulation in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Familial primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Genetic factors in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Immunogenetics of chronic liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

A new peak in the ALPS

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Cirrhosis of the Liver induced in Rabbits by Gastric Instillation of 3-Monohydroxycholanic Acid

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Tauroursodeoxycholate prevents taurocholate induced cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Involvement of microtubules in the swelling-induced stimulation of transcellular taurocholate transport in perfused rat liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Dihydroxy bile acids activate the transcription of cyclooxygenase-2

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Liver cirrhosis induces renal and liver phospholipase A2 activity in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Cholangitis associated with paroxysmal nocturnal hemoglobinuria: another instance of ischemic cholangiopathy?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Peribiliary vascular plexus in primary sclerosing cholangitis and primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Sclerosing cholangitis: broad spectrum of radiographic features

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Small-duct primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

Recurrence of primary sclerosing cholangitis following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980421-3

7 January 2021

10.1016/S0168-8278(00)80421-3

Identifiers

DOI

1 reference

29 July 2017

1 reference